Blockade of PD-1, CTLA-4, and TIM-3 can enhance cetuximab-based cancer immunotherapy to reverse CD8+ tumor-infiltrating lymphocytes dysfunction, thus affecting the prognosis of cancer patients [35]. Here, CTLA4 is linked to neoplasm.